Literature DB >> 11326015

Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials.

R R Reinert1, C von Eiff, M Kresken, J Brauers, D Hafner, A Al-Lahham, H Schorn, R Lütticken, G Peters.   

Abstract

In a prospective multicenter study (1996 to 1999), 156 episodes of bacteremic streptococcal infections of neutropenic patients were evaluated. Streptococcus oralis (26.3%), S. pneumoniae (26.3%), S. agalactiae (11.5%), S. mitis (9%), and S. pyogenes (5.8%) were the predominant species. Four strains (2.6%) were found to be intermediately resistant to penicillin. One strain (0.6%) was found to be highly resistant to penicillin (MIC, 8 mg/liter). Reduced susceptibility to penicillin was detected among S. oralis (14.6%), S. mitis (7.1%), and S. pneumoniae (4.9%) isolates but was not recorded among S. agalactiae and S. pyogenes. Resistance rates and intermediate resistance rates for other antimicrobials were as follows (all species): amoxicillin, 1.3 and 3.2%; erythromycin, 16 and 2.6%; clindamycin, 5.8 and 0%; ciprofloxacin, 1.9 and 7.7%. Quinupristin-dalfopristin showed good in vitro activity against most streptococcal isolates (MIC at which 50% of the isolates were inhibited [MIC(50)], 0.5 mg/liter; MIC(90), 1 mg/liter, MIC range, 0.25 to 4 mg/liter).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11326015      PMCID: PMC88050          DOI: 10.1128/JCM.39.5.1928-1931.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci.

Authors:  C von Eiff; G Peters
Journal:  Zentralbl Bakteriol       Date:  1996-04

2.  Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae isolates causing systemic infections among children in Germany, 1992 to 1996.

Authors:  R R Reinert; A Kaufhold; J J Schlaeger; V Mechery; R Lütticken
Journal:  Pediatr Infect Dis J       Date:  1997-02       Impact factor: 2.129

Review 3.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

Authors:  S F Altschul; T L Madden; A A Schäffer; J Zhang; Z Zhang; W Miller; D J Lipman
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

4.  Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994.

Authors:  R R Reinert; A Queck; A Kaufhold; M Kresken; R Lütticken
Journal:  Clin Infect Dis       Date:  1995-12       Impact factor: 9.079

5.  Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.

Authors:  M A Pfaller; R N Jones; S A Marshall; M B Edmond; R P Wenzel
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

Review 6.  Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.

Authors:  E Rubinstein; F Bompart
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

7.  Application of the polymerase chain reaction to study the M protein(-like) gene family in beta-hemolytic streptococci.

Authors:  A Podbielski; B Melzer; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

8.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

Authors:  G V Doern; M J Ferraro; A B Brueggemann; K L Ruoff
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.

Authors:  P H McWhinney; S Patel; R A Whiley; J M Hardie; S H Gillespie; C C Kibbler
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more
  2 in total

Review 1.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

2.  Species-specific difference in antimicrobial susceptibility among viridans group streptococci.

Authors:  Sejong Chun; Hee Jae Huh; Nam Yong Lee
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.